ARS Pharmaceuticals (SPRY) Notes Payables (2021)

ARS Pharmaceuticals' (SPRY) quarterly Notes Payables came in at $3.5 million in Q4 2021.

ARS Pharmaceuticals (SPRY) Notes Payables (2021) Analysis & Trends

ARS Pharmaceuticals has disclosed Notes Payables across 1 years of filings, most recently posting $3.5 million for Q4 2021.

Notes Payables for Q4 2021 came in at $3.5 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2021 was $3.5 million (changed N/A YoY), and the FY2021 annual result was $3.5 million, changed N/A from the prior year.
Notes Payables came in at $3.5 million for Q4 2021 at ARS Pharmaceuticals.
In the past five years, Notes Payables ranged from a high of $3.5 million in Q4 2021 to a low of $3.5 million in Q4 2021.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	ARS Pharmaceuticals	954.24 Mn	753.27 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2021	3.48 Mn